Sarcopenia in moderately severe/severe acute pancreatitis: SARCOPANC

• Research type

  Research Study

• Full title

  Prospective longitudinal evaluation of Sarcopenia, health related quality of life and correlation with blood and stool-based microbiome in moderately severe and severe acute pancreatitis: SARCOPANC Study

• IRAS ID

  331788

• Contact name

  Sanjay Pandanaboyana

• Contact email

  s.pandanaboyana@nhs.net

• Sponsor organisation

  Newcastle upon Tyne Hospitals Charity

• Duration of Study in the UK

  2 years, 9 months, 29 days

• Research summary

  Sarcopenia: Sarcopenia is a syndrome characterised by progressive and generalised loss of skeletal muscle mass and strength. Sarcopenia is now formally recognised as a muscle disease with an ICD-10-MC Diagnosis Code. Sarcopenia in clinical terms is associated with high personal, social and economic burdens. When untreated increases the risk of falls and fractures, impairs ability to perform activities of daily living and is associated with cardiac disease, respiratory disease and cognitive impairment and contributes to lowered quality of life, loss of independence or need for long-term care placement, and death. Furthermore, it significantly increases health care costs from risk of prolonged hospitalisation and rehabilitation. The European Working Group on Sarcopenia in Older People (ESGSOP) recommends using the presence of both low muscle mass and low muscle function (strength or performance) for the diagnosis of sarcopenia. Sarcopenic obesity is defined as the co-existence of obesity and sarcopenia. Recent studies have shown an association between elements of sarcopenia with blood immune profile and immunosenescence however baseline and longitudinal data in acute pancreatitis patients are lacking.
  Aims of the study:
  Aim 1: Prospective longitudinal clinical assessment of sarcopenia with QOL, PROMS and occupational health data in a cohort of SAP/ MSAP patients from 6 hospital at admission, discharge,6 and 12 months follow up.
  Aim 2: Prospective evaluation of biomarkers and gut microbiome related to sarcopenia at the same time points

• REC name

  Yorkshire & The Humber - Sheffield Research Ethics Committee

• REC reference

  24/YH/0145

• Date of REC Opinion

  26 Jul 2024

• REC opinion

  Further Information Favourable Opinion